Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5

Journal of Medicinal Chemistry

Volumn 46, Issue 4, 2003, Pages 486-498

  Peukert, Stefan ^a   Brendel, Joachim ^a   Pirard, Bernard ^a   Brüggemann, Andrea ^a   Below, Peter ^a   Kleemann, Heinz Werner ^a   Hemmerle, Horst ^a,b   Schmidt, Wolfgang ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' [(4 METHOXYBENZOYLAMINO)METHYL]BIPHENYL 2 CARBOXYLIC ACID 2,4 DIFLUOROBENZYLAMIDE; [2' (2 PYRIDIN 2 YLETHYLCARBAMOYL)BIPHENYL 2 YLMETHYL]CARBAMIC ACID 1 PHENYLETHYL ESTER; [2' (2 PYRIDIN 2 YLETHYLCARBAMOYL)BIPHENYL 2 YLMETHYL]CARBAMIC ACID BENZYL ESTER; ALMOKALANT; ANTIARRHYTHMIC AGENT; DOFETILIDE; IBUTILIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SOTALOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HYDROPHOBICITY; NONHUMAN; OOCYTE; PHARMACOPHORE; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; XENOPUS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BIPHENYL COMPOUNDS; HUMANS; ION CHANNEL GATING; KV1.5 POTASSIUM CHANNEL; MODELS, MOLECULAR; OOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS;

EID: 0037434547     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0210461     Document Type: Article

References (38)

1. Kannel, W. B.; Wolf, P. A.; Benjamin, E. J.; Levy, D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population based estimates. Am. J. Cardiol. 1998, 82, 2N-9N.
2. Gerlach, U. IKs channel blockers: potential antiarrhythmic agents. Drugs Future 2001, 26, 473-484.
3. Pratt, C. M.; Moye, L. A. The cardiac arrhythmia suppression trial: background, interim results and implications. Am. J. Cardiol. 1990, 65 (4), 20B-29B.
4. Waldo, A. L.; Camm, A. J.; Deruyther, H.; Friedman, P. L.; MacNeil, D. J.; Pauls, J. F, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996, 348, 7-12.
5. Bril, A. Recent advances in arrhythmia therapy: treatment and prevention of atrial fibrillation. Curr. Opin. Pharmacol. 2002, 2 (2), 154-159.
6. Nattel, S.; Hadjis, T. Talajic M. The treatment of atrial fibrillation. Drugs 1994, 48, 345-371.
7. + currents in isolated guinea-pig cardiomyocytes. Jpn. J. Pharmacol. 2000, 82, 1-12.
8. + current in human ventricular myocytes. Circ. Res. 1996, 78, 689-696.
9. Feng, J.; Wible, B.; Wang, Z.; Nattel, S. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ. Res. 1997, 80, 572-579.
10. Amos, G. J.; Wettwer, E.; Metzger, F.; Li, Q.; Himmel, H. M.; Ravens, U. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J. Physiol. (London) 1996, 491, 31-50.
11. Wang, Z.; Fermini, B.; Nattel, S. Sustained depolarization-induced outward current in human atrial myocytes. Circ. Res. 1993, 73, 1061-1076.
12. Nattel, S.; Yue, L.; Wang, Z.; Cardiac ultrarapid delayed rectifiers. Cell Physiol. Biochem. 1999, 9, 217-226.
13. + channels. In Ion channels and disease; Academic Press: San Diego, 2000; pp 97-123.
14. Feng, J.; Xu, D.; Wang, Z.; Nattel, S. Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am. J. Physiol. 1998, 275, H1717-H1725.
15. Schaffer, P.; Pelzmann, B.; Bernhart, E.; Lang, P.; Lökebö, J. E.; Mächler, H. et al. Estimation of outward currents in isolated human atrial myocytes using inactivation time course analysis. Pflügers Arch. - Eur. J. Physiol. 1998, 436, 457-468.
16. Nygren, A.; Leon, L. J.; Giles, W. R. Simulations of the human atrial action potential. Philos. Trans. R. Soc. London A. 2001, 359, 1111-1125.
17. Nygren, A.; Fiset, C.; Firek, L.; Clark, J. W.; Lindblad, D. S.; Clark, R. B. et al. Mathematical model of an adult human atrial cell. Circ. Res. 1998, 82, 63-81.
18. Courtemanche, M.; Ramirez, R. J.; Nattel, S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc. Res. 1999, 42, 477-489.
19. Brendel, J.; Peukert, S. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Exp. Opin. Ther. Pat. 2002, 12 (11), 1589-1598.
20. Icagen; Eli Lilly & Co.; WO9804521, 1998.
21. Icagen; WO9937607, 1999.
22. Icagen; Eli Lilly & Co.; WO9962891, 1999.
23. Matsuda, T.; Masumiya, H.; Tanaka, N.; Yamashita, T.; Tsuruzoe, N.; Tanaka, Y. et al. Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sci. 2001, 68 (17), 2017-2024.
24. Merck & Co. In.; WO0224655, 2002.
25. Aventis SA.; WO0125189, 2001 and WO0246162, 2002.
26. UNITY Chemical Information Software, Version 4.1.1; Tripos, Inc.: St. Louis, MO, 2000.
27. Brandmeier, V., Feigel, M. A macrocycle containing two biphenyl and two alanine subunits. Synthesis and conformation in solution. Tetrahedron 1989, 45 (5), 1365-1376.
28. Brandmeier, V.; Sauer, W. H. B.; Feigel, M. Antiparallel β-sheet conformation in cyclepeptides containing a pseudo-amino acid with a biphenyl moiety. Helv. Chim. Acta 1994, 77 (1), 70-85.
29. Abbaszadeh, M. R.; Bowden, K. Intramolecular catalysis. Part 4. The intramolecular Cannizzaro reaction of biphenyl-2,2′-dicarboxaldehyde, [α-,α′-2H2]biphenyl-2,2″-dicarboxaldehyde and 4,4′- or 5,5′- or 6,6′-disubstituted biphenyl-2,2′-dicarboxaldehydes. J. Chem. Soc., Perkin Trans. 2 1990, 12, 2081-2087.
30. Tichy, M.; Holanova, J.; Zavada, J. ω-Amino acids and lactams with chiral biaryl axis. Tetrahedron: Asymmetry 1998, 9, 3497-3504.
31. Guillier, F.; Nivoliers, F.; Godard, A.; Marsais, F.; Queguinier, G.; Siddiqui, M. A.; Snieckus, V. Combined metalation-palladium-catalyzed cross coupling strategies. A formal synthesis of the marine alkaloid amphimedine. J. Org. Chem. 1995, 60, 292-296.
32. Finch, H.; Reece, D. H.; Sharp, J. T.; An efficient general route to furo-, pyrido- and thieno-[d] [2]benzazepines via Pd catalyzed cross coupling reactions and nitrile ylide cyclisations. J. Chem. Soc., Perkin Trans 1 1994, 1993-1203.
33. Watanabe, M.; Shinoda, E.; Shimizu, Y.; Furukawa, S.; Iwao, M.; Kuraishi, T. Synthesis of bostrycoidin via directed lithiation of tertiary nicotinamide. Tetrahedron 1987, 43(22), 5281-5286.
34. Pirard, B. et al. Pharmacophore identification for two chemical classes of Kv1.5 blockers. Unpublished results.
35. r blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naun. Schmied. Arch. Pharmacol. 2002, 366, 482-487.
36. DeVita, R. J.; Bochis, R.; Frontier, A. J.; Kotliar, A.; Fisher, M. H.; Schoen. W. R. etal. A potent, orally bioavailable benzazepinone growth hormone secretagogue. J. Med. Chem. 1998, 41, 1716-1728.
37. Hilper K.; Ackermann, J.; Banner, D. W.; Gast, A.; Gubernator, K.; Hadvary, P. et al. Design and synthesis of potent and highly selective thrombin inhibitors. J. Med. Chem. 1994, 37, 3889-3901.
38. Golding, A. L. Maintenance of Xenopus laevis and oocyte injection. Methods Enzymol. 1992, 207, 266-279.